Business Context and Reporting Period
This Form 8-K reports on events occurring at the Annual Meeting of Stockholders for aTyr Pharma, Inc. held on May 6, 2020. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "LIFE". The filing details the departure of a director, the election of new directors, and the approval of several corporate governance and equity plan amendments.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Shareholder Actions
- Director Departure: James C. Blair, Ph.D., completed his term as a Class II director and did not stand for reelection. The filing states this decision was not due to any disagreement with management.
- Director Elections: Two new Class II directors, Timothy P. Coughlin and Jane A. Gross, Ph.D., were elected to serve until the 2023 Annual Meeting.
- Equity Plan Amendment: Stockholders approved an amendment to the 2015 Stock Option and Incentive Plan to increase the number of shares reserved for issuance by 350,000 shares.
- Authorized Share Increase: Stockholders approved an amendment to the Restated Certificate of Incorporation to increase the authorized common stock from 10,714,286 to 21,425,000 shares.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
Voting Results and Management Commentary
All five proposals submitted to the stockholders were approved. A total of 9,352,498 shares were entitled to vote, with 8,545,708 shares present or represented by proxy.
| Proposal | Votes For | Votes Against | Abstentions/Withheld |
|---|---|---|---|
| Election of Timothy P. Coughlin | 5,197,550 | 1,896,670 (Withheld) | 1,451,488 (Broker Non-Vote) |
| Election of Jane A. Gross | 6,995,389 | 98,831 (Withheld) | 1,451,488 (Broker Non-Vote) |
| Ratification of Ernst & Young LLP | 8,459,698 | 85,325 | 685 |
| Amendment to 2015 Stock Plan (+350k shares) | 6,710,703 | 375,289 | 8,228 |
| Increase Authorized Shares to 21.4M | 7,513,665 | 1,003,071 | 28,972 |
| Adjournment Authority | 7,407,379 | 1,026,784 | 111,545 |
Management commentary is limited to the statement that Dr. Blair's departure was not related to any disagreement with the company's operations or policies.
Key Facts for Investor Verification
- Verify the impact of the 350,000 share increase to the 2015 Stock Option Plan on potential future dilution.
- Confirm the implications of doubling the authorized share count to 21,425,000 shares for future capital raising activities.
- Review the full text of the amended 2015 Plan (Exhibit 10.1) for specific terms regarding vesting and exercise prices.
- Note that the filing contains no financial data; verify current cash runway and burn rate in recent quarterly reports.